RxDoctor Payments Data

Daniel Cohen, MD

Internal Medicine · Lee, MANPI 1285692129

Payments from drug & device makers

$3,701in general payments, 2019–2025

Across 205 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$536
  • Lundbeck LLC$435
  • AstraZeneca$358
  • GSK$302
  • Novo Nordisk$231
  • Johnson & Johnson$222
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$3,701100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,701 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$166,580
Medicare patients
370
Services billed
2,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$92,769
OzempicSemaglutide47$53,426
XareltoRivaroxaban39$51,642
JardianceEmpagliflozin32$44,410
Repatha SureclickEvolocumab26$22,907
FarxigaDapagliflozin Propanediol15$22,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,197
Praluent PenAlirocumab29$17,292
JanuviaSitagliptin Phosphate14$16,733
Breo ElliptaFluticasone/Vilanterol19$13,788
Incruse ElliptaUmeclidinium Bromide28$11,569
Rosuvastatin Calcium206$6,727
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,069
GemtesaVibegron12$5,809
Atorvastatin Calcium386$4,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$536$94,137114 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$302$54,564100 claims
Novo NordiskOzempic$231$53,42647 claims
Johnson & JohnsonXarelto$222$51,64239 claims
Boehringer IngelheimJardiance$49$44,41032 claims
AstraZenecaFarxiga$358$22,42115 claims
MerckJanuvia$85$16,73314 claims
Sumitomo Pharma America, Inc.Gemtesa$107$5,80912 claims
Scilex Pharmaceuticals Inc.Colchicine$22$1,08616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Lee

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →